## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# PREMARKET TOBACCO PRODUCT APPLICATION (PMTA) AMENDMENT AND GENERAL CORRESPONDENCE SUBMISSION

Form Approved: OMB No. 0910-0879 Expiration Date: xx/xx/20xx

Paperwork Reduction Act Statement: The Paperwork Reduction Act of 1995 provides that an agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0910-0879. The time required to complete this information collection is estimated to average 10 minutes per response. Send comments regarding this burden estimate or any other aspects of this collection of information, including suggestions for reducing burden to PRAStaff@fda.hhs.gov.

Marketing a New Tobacco Product without a Marketing Granted Order (MGO) i is illegal and may be subject to enforcement.

Please carefully read the instructions located in the Appendix before completing this form.

## SECTION I - APPLICANT IDENTIFICATION1

## Part A: Applicant Information<sup>1</sup>

The applicant is the individual or organization (manufacturer/importer) seeking a marketing granted order for a new product. Complete for either an organization or an individual, NOT both. Organization applicants should complete fields 1–20 only. Individual applicants should complete fields 21–36 only.

If applicant is an organization, complete Part A fields 1–20.									
1. Organization Name				2. Other Organization Names (if applicable)					
Organization FDA-As     Establishment Identifi					4. Or	ganiza	ation D&B D	UNS® Nu	mber
5. Submit Date (mm/dd/	<i>(yyyy)</i>	6. Stree	t Addres	ss Line	1			7. Stree Suite, B	t Address Line 2 (Apt., Idg., #)
8. City	9. State	, Province	e, or Ter	ritory	10. C	ountry	/		11. ZIP or Postal Code
Point of Contact for O	rganizatio	1							
12. First Name			13. Mi	ddle Init	ial	al 14. Last Name			
15. Generational Suffix	16. Profess	sional Suff	fix	17. Po	sition	Title			
18. Phone Number		19. Fax	Numbe	r	20. Email Address				
If applicant is an indiv	idual, com	plete field	ds 21–3	6 and p	rocee	d to F	Part B.		
21. First Name		22. Middle	Initial	23. La	ast Name 24. Submit Date (mm/dd/yyy			mit Date (mm/dd/yyyy)	
25. Generational Suffix 26. Professional Suffix 27. Po			27. Po	sition	Title				
28. Street Address Line 1					29. Street Address Line 2 (Apt., Suite, Bldg., #)			(Apt., Suite, Bldg., #)	
30. City	30. City 31. State, Province, or Territory			erritory	32. C	ountry	/		33. ZIP or Postal Code
34. Phone Number 35. Fax Number			36. Email Address						

Don't Dr. Ordensianian Time
Part B: Submission Type
1. Identify the type of submission (select one):
☐ Amendment (if selected, proceed to Section II)
☐ General Correspondence (if selected, skip Section II and proceed to Section III)
SECTION II – AMENDMENT INFORMATION
Part A: Amendment Purpose
1. List the FDA Submission Tracking Number (STN) and Product Identifier (PD) Number, or STN.PD# (e.g., PM5679840.PD1), assigned to the application being amended.
2. Select the subject(s) of the amendment (select all that apply):
☐ Response to Deficiency Letter
☐ Response to Environmental Information Request Letter
☐ Response to Information Request Letter
☐ Request for Extension of Time to Respond to Deficiency Letterr
☐ Request to Withdraw the PMTA Report  —If selected, provide the name and STN.PD# of product(s) being withdrawn:
☐ Select to indicate that the withdrawal is due to a health or safety concern related to the tobacco product.
☐ Update to Unique Identification Information —If selected, you must provide FDA Form 4057b for any amended product properties with this submission and an STN.PD# in Additional Properties.
☐ Update Product Properties —If selected, provide updates in Section II.C below.
☐ Submit Adverse Experience Report —If selected, provide submission summary in Section II.A.3 below.
☐ Change in Cross-Referenced Content .
☐ Change in Related Submissions
☐ Change in Tobacco Product Master File Referenced
☐ Letter of Authorization (LOA)
☐ Change in Submission Contents —If selected, provide submission summary in Section II.A.3 below.
☐ Other —If selected, provide submission summary in Section II.A.3 below.

Part B: Update to Product Properties (if applicable) Use this section if you selected "Update Product Properties" in Section II.A.2 and you are amending previously submitted product property information									
Update to New Product Properties									
1. New Produc Name	t 2. STN. PD#	3. Action	4. Property Name	5. Previously Submitted Target Value	6. Updated Target Value				

3. Summarize the submission in the space provided, if you selected "Submit Adverse Experience Report," "Change in

Submission Contents," or "Other" in Section II.A.2:

Continuation Page for Update to New Product Properties

Part C: Cross-Referenced Information (Optional)
Use this section if you selected "Change in Cross-Referenced Content" in Section II.A.2 and you are adding, updating, or removing any cross-referenced content.

1. Cross- Referenced STN	2. Action	3. Is the content relevant to all product(s) within this submission?	4. Information and sections to be referenced
		☐ Yes ☐ No (list applicable product name[s]):	
		☐ Yes ☐ No (list applicable product name[s]):	
		☐ Yes ☐ No (list applicable product name[s]):	
		☐ Yes ☐ No (list applicable product name[s]):	
		☐ Yes ☐ No (list applicable product name[s]):	
		☐ Yes ☐ No (list applicable product name[s]):	
		☐ Yes ☐ No (list applicable product name[s]):	

Continuation Page for Cross-Referenced Content

## Part D: Related Submissions

Use this section if you selected "Change in Related Submissions" in Section II.A.2 and you are adding, updating, or removing any related submissions content.

1. Related Submission(s) STN	2. Action	3. Is the content relevant to all product(s) within this submission?	4. Information and sections to be referenced
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	

Continuation Page for Related Submissions

## Part E: Referenced Tobacco Product Master File(s) (TPMF) (Optional)

Use this section if you selected "Change in Tobacco Product Master File Referenced" in Section II.A.2 and you are adding, updating, or removing any referenced TPMFs. Complete fields 1–6 for each amended TPMF cross-reference. Use the Continuation Page button below to list additional TPMFs.

1. TPMF Owner 2. TF		FPMF STN (assigned by FDA)		3. Action Choose an action.	
4. Is the content applicable to all products within this submission?		☐ Yes	☐ No (list applica	ble product name[s]):	
5. Information and sections to be referenced (e.g., all sections, sections I–III)					
6. Right of reference included		☐ Yes	□ No		
1. TPMF Owner	2. T	PMF STN (ass	igned by FDA)	3. Action Choose an action.	
4. Is the content applicable to all products within this submission?		☐ Yes	☐ No (list applica	ble product name[s]):	
5. Information and sections to be referenced (e.g., all sections, sections I–III)					
6. Right of reference included		☐ Yes	□ No		
1. TPMF Owner	2. T	PMF STN (ass	igned by FDA)	3. Action Choose an action.	
4. Is the content applicable to all products within this submission?		☐ Yes	☐ No (list applica	ble product name[s]):	
5. Information and sections to be referenced (e.g., all sections, sections I–III)					
6. Right of reference included		☐ Yes	□ No		

Continuation Page for Referenced TPMF

	Location:	
	Location:	
	Location:	
<b>.</b>		
<i>,</i>		
7.		
	Location:	
3.		····
	Location:	
ert i	t G: Certification Statement rt the name of the authorized representative(s) or U.S. agretatement.	ent and the name of the organization being represented in the boo
Ι (	I (name of responsible official)	, on behalf of the applicant (name of
аµ	applicant), hereby cer	rtify the applicant will maintain all records to substantiate
th	the accuracy of this application for the period of time	e required in 21 CFR 1114.45 and ensure that such records
re	remain readily available to FDA upon request. I cert	ify that this information and the accompanying submission
ar	are true and correct, that no material fact has been	omitted, and that I am authorized to submit this on the
ap	applicant's behalf. I understand that under section 1	001 of title 18 of the United States Code anyone who
kr	knowingly and willfully makes a materially false, ficti	itious, or fraudulent statement or representation in any
m	matter within the jurisdiction of the executive, legisla	ative, or judicial branch of the Government of the United
	States is subject to criminal penalties.	

**Part F: Amendment Contents** 

## SECTION III - GENERAL CORRESPONDENCE INFORMATION

## **Submission Information for General Correspondence**

1. Subject of Correspondence (select all that apply):
<ul> <li>Change in Authorized Representative, U.S. Agent, Manufacturer, or Point of Contact</li> <li>If selected, complete Section III Part A below.</li> </ul>
☐ Request for Change in Ownership —If selected, complete Section III Part B below.
☐ Submit Adverse Experience Report —If selected, provide submission summary in Section III field 2 below.
☐ Request to Withdraw Previously Submitted General Correspondence —If selected, provide submission summary in Section III field 2 below.
☐ Meeting Request —If selected, complete Section III Part C below.
☐ Other —If selected, provide submission summary in Section III field 2 below.
2. Summarize the correspondence in the space provided if you selected "Submit Adverse Experience Report," "Request to Withdraw Previously Submitted General Correspondence," or "Other" in Section III field 1:
art A: Add, Update, or Remove Applicant Information or Point of Contact (Optional) complete this section if you selected "Change in Authorized Representative, U.S. Agent, Manufacturer, or Point of Contact information" in Section III field 1 and you are updating previously submitted contact information. Use the Continuation Page button elow to list additional changes in applicant information or points of contact.
. Select only one:
Choose an action.
–If "Update" is selected, provide a brief description of the update here:
. Select the type of contact (select one):
☐ Applicant ☐ Authorized Representative ☐ U.S. Agent (Address and contact information only)
☐ Manufacturer ☐ Contract Manufacturer ☐ Repacker/Relabeler ☐ Other

•			current FDA submissions	s?			
☐ Yes [	⊔ No (li	st applic	able STNs.PD#s):				
4. Effective Date	of Chang	e (mm/d	d/yyyy)				
Current Contact	t Informa	tion on	Record	Added/Updated	Contact	Informa	ntion
5. First Name	e 6. 7. Last Name Middle Initial			23. First Name	24. Middle Initial	25. Las	t Name
8. Generational 9. Professional Suffix Suffix			26. Generation- al Suffix	27. Prof	27. Professional Suffix		
10. Position Title				28. Position Title			
11.Organization N	Name			29.Organization	Name		
		13. Organization D&B DUNS® Number		FDA-Assigned F	FDA-Assigned Facility Establishment Identifier		ganization D&B DUNS® er
14. Street Address Line 1			15. Street Address Line 2 (Apt., Suite, Bldg., #)	32. Street Addres	32. Street Address Line 1		33. Street Address Line 2 (Apt., Suite, Bldg., #)
16. City 17. Sta		te, Province, or y	34. City	1 1		35. State, Province, or Territory	
18. Country		19. ZIP or Postal Code	36. Country	36. Country		37. ZIP or Postal Code	
20. Phone Numb	er	21. Fax	Number	38. Phone Numb	er	39. Fax	Number
22. Email Addres	S			40. Email Addres	SS		

Continuation Page for Part A

Part B: Request for Change in Complete this section if you selected field 1 and the correspondence include	"Request for Change in Own	nership" in Section III Submission for General Correspondence ownership.
Applications, submissions, and and Product Identifier PD Nun (Optional: Applicants may product)	nber (STN.PD#):	nsferred including the FDA Submission Tracking Number
STN	PD Number (if applicable)	Product Name (if applicable)
2. Effective Date of Change (mm	 /dd/yyyy)	
☐ The specific applications ☐ A statement that all right ☐ Contact information for the left ☐ A signed letter from the left ☐ The specific applications ☐ A statement committing contained in the application of the left ☐ A statement that the new amendments and record ☐ A statement that no mode.	ship request letter from the s, submissions, and products of the applications have the new applicant (name, row applicant accepting the s, submissions, and product o all agreements, promise tions and submissions.  It is a complete that are required to be known and submissions and submissions.	former applicant must include: ct names by STN being transferred. been transferred to the new applicant. mailing address, phone number, and email). change in ownership from the former applicant must include: ct names by STN being accepted. es, and conditions made by the former applicant of record e copy of the applications and submissions including tept, or state they will request a copy per 21 CFR 20.40. e to the transferred tobacco applications and submissions. mailing address, phone number, and email).
		Continuation Page for Part B

Part C: Meeting Request  Complete this section if you selected "Meeting Request" in Section III Submission for General Correspondence field 1 and the correspondence includes a meeting request.						
1. Meeting Topic						
2. Meeting Purpose						
3. Meeting Format						
4. Is the meeting inform	nation package include	ed?				
☐ Yes ☐ No	(provide expected da	ate of submission (mm/dd/yyyy)):	<del></del>			
Products to be Discu	ussed at Meeting					
5. Product Name	6. Product Use	7. Product Category (if applicable)	8. STN.PD# (if applicable)			
9. This meeting request contains the following items (select all that apply):						
☐ A preliminary list of the specific objectives/outcomes expected from the meeting.						
☐ A preliminary proposed agenda, including an estimate of the time needed and a designated speaker for each agenda item.						
☐ A preliminary list	of specific critical que	stions, grouped by discipline (e.g., cher	nistry, clinical, non-clinical).			
<ul> <li>□ A preliminary list of specific critical questions, grouped by discipline (e.g., chemistry, clinical, non-clinical).</li> <li>□ A list of all individuals who will attend the meeting on your behalf, including titles and responsibilities.</li> </ul>						

Continuation Page for Part C

## **SECTION VII – APPENDICES**

## **CONTINUATION PAGES**

## Appendix A: Update to Product Properties (if applicable)

Submit a single Form FDA 4057a including all continuation additional page information. For Continuation Page entries requiring extra space to provide additional information, use the sections provided below. Fill out as many additional sections as needed, completing all fields within each section.

## **SECTION II, Part B: Update to Product Properties (if applicable)**

## **Update to New Product Properties**

1. New Product Name	2. STN. PD#	3. Action	4. Property Name	5. Previously Submitted Target Value	6. Updated Target Value
		Choose an action.			
		Choose an action.			
		Choose an action.			
		Choose an action.			
		Choose an action.			
		Choose an action.			
_		Choose an action.			
_		Choose an action.			

## **Appendix B: Cross-Referenced Content**

Submit a single Form FDA 4057a including all continuation additional page information. For Continuation Page entries requiring extra space to provide additional information, use the sections provided below. Fill out as many additional sections as needed, completing all fields within each section.

## **SECTION II, Part C: Cross-Referenced Content**

1. Cross- Referenced STN	2. Action	3. Is the content relevant to all product(s) within this submission?	4. Information and sections to be referenced
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
	l .	1	I .

## **Appendix C: Related Submissions**

Submit a single Form FDA 4057a including all continuation additional page information. For Continuation Page entries requiring extra space to provide additional information, use the sections provided below. Fill out as many additional sections as needed, completing all fields within each section.

## **SECTION II, Part D: Related Submissions**

1. Related Submission(s) STN	2. Action	3. Is the content relevant to all product(s) within this submission?	4. Information and sections to be referenced
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	
		☐ Yes	
		☐ No (list applicable product name[s]):	

## Appendix D: Referenced Tobacco Product Master File(s) (TPMF)

Submit a single Form FDA 4057a including all continuation additional page information. For Continuation Page entries requiring extra space to provide additional information, use the sections provided below. Fill out as many additional sections as needed, completing all fields within each section.

## SECTION III, Part E: Referenced Tobacco Product Master File(s) (TPMF) (Optional)

1. TPMF Owner	2. TPMF STN (assigned	by FDA) 3. Action Choose an action.
4. Is the content applicable to all products within this submission?	☐ Yes ☐ No	(list applicable product name[s]):
5. Information and sections to be referenced (e.g., all sections, sections I–III)		
6. Right of reference included	☐ Yes ☐ No	
1. TPMF Owner	2. TPMF STN (assigned	by FDA)  3. Action  Choose an action.
4. Is the content applicable to all products within this submission?	☐ Yes ☐ No	(list applicable product name[s]):
5. Information and sections to be referenced (e.g., all sections, sections I–III)		
6. Right of reference included	☐ Yes ☐ No	
1. TPMF Owner	2. TPMF STN (assigned	by FDA) 3. Action Choose an action.
4. Is the content applicable to all products within this submission?	☐ Yes ☐ No	(list applicable product name[s]):
5. Information and sections to be referenced (e.g., all sections, sections I–III)		
6. Right of reference included	☐ Yes ☐ No	

## Appendix E: Add, Update, or Remove Applicant Information or Point of Contact (Optional)

Submit a single Form FDA 4057a including all continuation additional page information. For Continuation Page entries requiring extra space to provide additional information, use the sections provided below. Fill out as many additional sections as needed, completing all fields within each section.

SECTION III, Part A: Add, Update, or Remove Applicant Information or Point of Contact (Optional)								
1. Select only one	e:							
Choose an action.								
–If "Updat	e" is sele	cted, pr	ovide a brief description o	of t	he update here:			
2. Select the type	of contac	ct (selec	t one):					
☐ Applicant ☐ Authorized Representative ☐ U.S. Agent (Address and contact information only)								
☐ Manufactur	er 🗆	Contra	act Manufacturer	R	Repacker/Relabele	er	☐ Oth	er
3. Is this change	applicable	e for all	current FDA submissions	?				
☐ Yes ☐	□ No <i>(li</i>	st applic	able STNs.PD#s):					
4. Effective Date	of Chang	e ( <i>mm/d</i>						
Current Contact	Informa	tion on	Record		Added/Updated Contact Information			
5. First Name	6. Middle Initial	7. Last	Name		23. First Name	24. Middle Initial	25. Las	t Name
8. Generational Suffix Suffix				26. Generation- al Suffix	27. Prof	27. Professional Suffix		
10. Position Title 28. Position Title								
11.Organization Name					29.Organization Name			
12. Organization FDA-Assigned Facility Establishment Identifier (FEI) Number			30. Organization FDA-Assigned Facility Establishment Identifier (FEI) Number					
		15. Street Address Line 2 (Apt., Suite, Bldg., #)				33. Street Address Line 2 (Apt., Suite, Bldg., #)		

18. Country		19. ZIP or Postal Code	36. Country	•	37. ZIP or Postal Code	
20. Phone Number 21. Fat		x Number	38. Phone Number 39. Fax Nun		I x Number	
22. Email Address			40. Email Address			
requiring extra space to p	A 4057a rovide a	pendix F: Request for Cha including all continuation a additional information, use a all fields within each section	additional page information the sections provided belo	n. For Cont		
SECTION III, Part B: Rec	uest fo	r Change in Ownership				
Applications, submissions, and product names to be transferred including the FDA Submission Tracking Number and Product Identifier PD Number (STN.PD#):     (Optional: Applicants may provide a separate list of submissions subject to transfer)						
STN		PD Number (if applicable)	Product Name (if applicable)			

Added/Updated Contact Information (cont.)

35. State, Province, or

Territory

34. City

**Current Contact Information on Record (cont.)** 

17. State, Province, or

Territory

16. City

## **Appendix G: Meeting Request**

Submit a single Form FDA4057a including all continuation additional page information. For Continuation Page entries requiring extra space to provide additional information, use the sections provided below. Fill out as many additional sections as needed, completing all fields within each section.

## **SECTION III, Part C: Meeting Request**

## **Products to be Discussed at Meeting**

5. Product Name	6. Product Use	7. Product Category (if applicable)	8. STN.PD# (if applicable)
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	
	Choose an item.	Choose a product category.	

## Appendix H: Instructions for Completion of SE Amendment and General Correspondence Submission Form

This form and the instructions are used solely to provide the applicant an organized format with which to supply information required for submission of a Premarket Tobacco Product Application (PMTA) Amendment and General Correspondence.

Form FDA 4057a – Premarket Tobacco Product Application (PMTA) Amendment and General Correspondence Submission is a required form for applicants submitting PMTA amendments or other general correspondence to FDA. The numbered items in the below instructions correspond to those provided on the form. Prior to submitting to FDA, ensure all information entered in each field is readable after saving.

## SECTION I — APPLICANT IDENTIFICATION

Section I should include information regarding the identity of the applicant, including the following parts:

- Part A: Applicant Information
- Part B: Submission Type

## Part A: Applicant Information

Part A should include information regarding the applicant for the submission. An applicant may be a manufacturer or importer that submits an SE Report to receive marketing authorization for a new tobacco product. Part A should be completed for either an organization applicant or an individual applicant, NOT both.

Note: Organization applicants should complete fields 1-20 only. Individual applicants should complete fields 21-36 only.

## If applicant is an organization, complete Part A fields 1–20 and proceed to Part B.

For these fields, provide the following information for the organization:

- **I.A.1.** The organization name is the party who takes responsibility for and initiates the submission of an SE application to FDA. The legal name of the organization may be an individual or company name (private or otherwise) and should match the applicant's Dun & Bradstreet Data Universal Numbering System D-U-N-S® (D&B DUNS®) number.
- I.A.2. All other names the applicant operates under (e.g., any "Doing Business As" [D.B.A.]), if applicable.
- **I.A.3.** The organization FDA-assigned Facility Establishment Identifier (FEI) number, if applicable. *Note:* To obtain or retrieve an FEI number, applicants can use the FEI Search Portal at <a href="https://www.accessdata.fda.gov/scripts/feiportal/index.cfm?action=portal.login">https://www.accessdata.fda.gov/scripts/feiportal/index.cfm?action=portal.login</a>, and/or contact FEI Search Portal support at <a href="mailto:feiportal@fda.hhs.gov">feiportal@fda.hhs.gov</a> for any FEI number-related questions.
- **I.A.4.** The organization D&B DUNS number, if applicable. *Note:* To obtain or retrieve a DUNS number, applicants can contact Dun and Bradstreet directly by phone at 1.866.705.5711 or through their website at <a href="https://www.dnb.com/duns/get-a-duns.html">https://www.dnb.com/duns/get-a-duns.html</a>.
- **I.A.5.** The submit date, or date you are formally submitting the application to FDA (e.g., submitting via the CTP Portal, the FDA Electronic Submissions Gateway [ESG], or handed to courier).
- **I.A.6.** The street address for the organization (including street number, street name and type, suffix direction, etc.). The street address cannot be a P.O. Box.
- **I.A.7.** Additional street address information for the organization location (including apartment, suite, or building number) that you were not able to include in I.A.6.
- **I.A.8.** The city of the organization location.
- **I.A.9.** The state, province, or territory of the organization location.
- **I.A.10.** The country of the organization location.
- **I.A.11.** The ZIP or postal code of the organization location.

## Point of Contact for Organization (only complete if applicant is an organization)

- **I.A.12.** The first name of the organization point of contact.
- **I.A.13.** The middle initial of the organization point of contact, if applicable.
- **I.A.14.** The last name of the organization point of contact.
- I.A.15. The generational suffix (e.g., Jr., III) of the organization point of contact, if applicable

- **I.A.16.** The professional suffix (e.g., M.D., Ph.D.) of the organization point of contact, if applicable.
- **I.A.17.** The professional position title of the organization point of contact.
- **I.A.18.** The phone number of the organization point of contact (include country code, if applicable, and area code).
- **I.A.19.** The fax number of the organization point of contact, if applicable (include country code, if applicable, and area code).
- **I.A.20.** The email address of the organization point of contact.

## If applicant is an individual, complete Part A fields 21–36 and proceed to Part B.

For these fields, provide the following information for the individual applicant:

- **I.A.21.** The first name of the individual applicant.
- **I.A.22.** The middle initial of the individual applicant, if applicable.
- **I.A.23.** The last name of the individual applicant.
- **I.A.24.** The submit date, or date you are formally submitting the application to FDA (e.g., submitting via the CTP Portal, the FDA Electronic Submissions Gateway [ESG], or handed to courier).
- I.A.25. The generational suffix (e.g., Jr., III) for the individual applicant, if applicable.
- I.A.26. The professional suffix (e.g., M.D., Ph.D.) for the individual applicant, if applicable.
- **I.A.27.** The professional position title of the individual applicant.
- **I.A.28.** The street address for the individual applicant (including street number, street name and type, suffix direction, etc.). The street address cannot be a P.O. Box.
- **I.A.29.** Additional street address information for the individual applicant (including apartment, suite, or building number) that you were not able to include in I.A.28.
- I.A.30. The city of the individual applicant.
- **I.A.31.** The state, province, or territory of the individual applicant.
- **I.A.32.** The country of the individual applicant.
- **I.A.33.** The ZIP or postal code of the individual applicant.
- **I.A.34.** The phone number of the individual applicant (include country code, if applicable, and area code).
- I.A.35. The fax number of the individual applicant, if applicable (include country code, if applicable, and area code).
- **I.A.36.** The email address of the individual applicant.

## Part B: Submission Type

- **I.B.1**. Select only one checkbox to indicate the type of submission:
  - Amendment if selected, proceed to Section II
  - General Correspondence if selected, skip Section II and proceed to Section III

Note: If you need to submit both an amendment and general correspondence, include two separate forms.

## **SECTION II — AMENDMENT INFORMATION**

Complete Section II if you selected "Amendment" as the submission type in Section I.B.1.

## Part A: Amendment Purpose

- **II.A.1.** List the PMTA being amended in the space provided; include the FDA Submission Tracking Number (STN) and Product (PD) Identifier, or STN.PD # (e.g., PM5679840.PD1)..
- **II.A.2.** Indicate the subject(s) of the Amendment (select all that apply).
  - *Note:* If you selected "Request to Withdraw the PMTA Submission," provide the product name and STN.PD# of the products to be withdrawn and select the additional checkbox if the withdrawal is due to a health or safety concern related to the tobacco product. If you selected "Update to Unique Identification Information," submit Form FDA 4057b with the STN.PD# in additional properties. If you selected "Update Product Properties," proceed to Section II.B.
- **II.A.3.** Summarize the submission in the space provided if you selected one of the following options in Section II.A.2:
  - Submit Adverse Experience Report
  - Change in Submission Contents
  - Other

## Part B: Update to Product Properties (if Applicable)

Complete Part B if you selected "Update Product Properties" in Section II.A.2 and are amending previously submitted product property information. This section is not for submitting changes to Unique Identification Information. This form cannot be used to add new products as an amendment. A new PMTA is required for additional products

### **Update(s) to New Product(s):**

Within this table, utilize a single row for each update to a new product. Use the Continuation Page button within the form to provide additional updates, as needed.

- **II.B.1.** The name of the new product.
- II.B.2. The STN.PD# for the new product, or FDA Submission Tracking Number (STN) and Product (PD )Identifier.
- **II.B.3.** Choose an option from the dropdown to indicate an action: add, update, or remove (previously submitted new product property information).
- II.B.4. The name of the property.
- II.B.5. The previously submitted target value.
- **II.B.6.** The updated target value.

## Part C: Cross-Referenced Content

Complete Part C if you selected "Change in Cross-Referenced Content" in Section II.A.2 for the addition, update, or removal of any cross-referenced content. Within the table, utilize a single row for each cross-reference. Use the Continuation Page button within the form to provide additional cross-references, as needed.

- II.C.1. Provide the FDA submission tracking number (STN) for the cross-referenced submission.
- **II.C.2.** Choose an option from the dropdown to indicate an action: add, update, or remove (the cross-referenced content).
- **II.C.3.** Identify if the cross-reference provided in column 1 is for all products in the submission. If the cross-reference is only for some of the new products in the submission, select "no" and list the name of the product(s) that reference the cross-reference.
- **II.C.4.** Identify what information in the cross-referenced submission you are seeking to reference for your new submission. For example, if you have the specific file name, document name, and page number, please list them.

## **Part D: Related Submissions**

Complete Part E if you selected "Change in Related Submissions" in Section II.A.2 for the addition, update, or removal of any related submissions. Within the table, utilize a single row for each related submission. Use the Continuation Page button within the form to provide additional related submissions, as needed.

- **II.D.1.** The FDA submission tracking number (STN) for the related submission.
- II.D.2. Choose an option from the dropdown to indicate an action: add, update, or remove (the related submission).
- **II.D.3.** Identify if the related submission provided in column 1 is for all products in the submission. If the related submission only applies to some of the new products in the submission, select "no" and list the name of the product(s) that reference the related submission.
- **II.D.4.** The location within the related submission that you are seeking to reference for your new submission. For example, list the specific file name, document name, and page number.

## Part E: Referenced Tobacco Product Master File(s) (TPMF) (Optional)

Complete Part E if you selected "Change in Tobacco Product Master File Referenced" in Section II.A.2 for the addition, update, or removal of any referenced TPMFs. Complete one table (fields 1–6) for each TPMF. Use the Continuation Page button within the form to provide additional TPMFs, as needed.

- **II.E.1.** Identify the TPMF owner.
- **II.E.2.** Provide the FDA submission tracking number (STN) of the TPMF. When a TPMF is established by FDA, the TPMF STN is provided to the owner and can be referenced by the TPMF owner and/or an authorized party. If the TPMF is not established at time of application submission, insert "N/A."
- **II.E.3.** Choose an option from the dropdown to indicate an action: add, update, or remove (the TPMF).
- **II.E.4.** Identify if the TPMF is applicable to all products in the submission. If the TPMF is only for some of the new products in the submission, select "no" and list the name of the product(s) that reference the TPMF.
- **II.E.5.** Identify what information in the TPMF you are seeking to reference for the new submission(s) and which sections in the TPMF are being referenced (e.g., all sections of the TPMF, sections I–III of the TPMF).
- **II.E.6.** Indicate if the right of reference is included in the submission. The TPMF owner may authorize another party to reference information contained within a TPMF through a right of reference such as a letter of authorization (LOA).

## Part G: Amendment Contents

Complete Part G to describe the items included in this amendment. For each item, provide a description of the content and indicate the file name and location of the content.

## Part G: Certification Statement

The application must contain the following certification, with the appropriate information inserted, as described in each parenthetical, signed by an authorized representative of the applicant.

- i. Certification Statement for Standard PMTAs is required for all PMTAs.
  - · Provide the name of the responsible official, or the authorized representative who is signing the certification.
  - Provide the name of the applicant being represented in the certification. Insert the name of the applicant as identified in Section I, Part A.
  - Provide the signature of the authorized representative of the applicant and the current date.

## SECTION III - GENERAL CORRESPONDENCE INFORMATION

Complete Section III if you selected "General Correspondence" as the submission type in Section I.B.1.

## **Submission Information for General Correspondence**

- **III.1.** Select the checkbox(es) to indicate the subject(s) of the Correspondence.
- **III.2.** Summarize the submission in the space provided, if you selected one of the following options in Section III.1.
  - Submit Adverse Experience Report
  - Request to Withdraw Previously Submitted General Correspondence
  - Other

## Part A: Add, Update, or Remove Applicant Information or Point of Contact (Optional)

Complete Part A if you selected "Change in Authorized Representative, U.S. Agent, Manufacturer, or Point of Contact" in Section III.1. for the addition, update, or removal of contact/address information for the applicant or another point of contact. Use the Continuation Page button within the form to list additional contact information updates, as needed.

- **III.A.1.** Select only one option from the dropdown to indicate an action: add, update, or remove (the contact/ address information).
  - Add Select to add a new party; if "Add" is selected, provide all contact information for the new party in fields 23–40. FDA may contact this new party to discuss the submission.
  - Update Select to change the contact information for an existing party; if "Update" is selected, provide the contact information as previously provided to FDA in fields 5–22 and the updated contact information in fields 23–40. FDA will update the Applicant Identification address or contact information that was previously submitted based on the updated information in field 23-40.
    - o Additionally, provide a brief description of the update in the space provided.
  - Remove Select to request that FDA remove an existing party on record. If "Remove" is selected, provide only the name of the party (Person's Name and/or Organization's Name) to be removed in fields 5–7 and/or 11. FDA will no longer contact the removed party to discuss to the submission.
- **III.A.2.** Select only one checkbox to indicate the type of contact whose information should be added updated/removed.
- **III.A.3.** Indicate whether this change is applicable for all current FDA submissions. If the change is only for some current submissions, select "no" and list the STN.PD#s that this change is applicable to.
- **III.A.4.** Indicate the date of the effective change.

## Complete fields 5-22 with contact information for the current, existing party.

- **III.A.5.** The first name of the current party.
- **III.A.6.** The middle initial of the current party, if applicable.
- **III.A.7.** The last name of the current party.
- **III.A.8.** The generational suffix (e.g., Jr., III) for the current party, if applicable.
- III.A.9. The professional suffix (e.g., M.D., Ph.D.) for the current party, if applicable.
- **III.A.10.** The professional position title of the current party.
- **III.A.11.** The organization name representing the current party.
- III.A.12. The organization FDA-assigned Facility Establishment Identifier (FEI) number, if applicable.
  Note: To obtain or retrieve an FEI number, applicants can use the FEI Search Portal at <a href="https://www.accessdata.fda.gov/scripts/feiportal/index.cfm?action=portal.login">https://www.accessdata.fda.gov/scripts/feiportal/index.cfm?action=portal.login</a>, and/or contact FEI Search Portal support at <a href="mailto:feiportal@fda.hhs.gov">feiportal@fda.hhs.gov</a> for any FEI number-related questions.
- **III.A.13.** The organization D&B DUNS number, if applicable.
- **III.A.14.** The street address for the current party (including street number, street name and type, suffix direction, etc.). The street address cannot be a P.O. Box.
- **III.A.15.** Additional street address information for the current party (including apartment, suite, or building number) that you were not able to include in III.A.14.
- III.A.16. The city of the current party.
- **III.A.17.** The state, province, or territory of the current party.
- III.A.18. The country of the current party
- **III.A.19.** The ZIP or postal code of the current party.
- III.A.20. The phone number of the current party (include country code, if applicable, and area code).
- III.A.21. The fax number of the current party, if applicable (include country code, if applicable, and area code).
- **III.A.22.** The email address of the current party.

## Complete fields 23–40 with contact information for the new/updated party.

- **III.A.23.** The first name of the new party.
- **III.A.24.** The middle initial of the new party, if applicable.
- **III.A.25.** The last name of the new party.

- **III.A.26.** The generational suffix (e.g., Jr., III) for the new party, if applicable.
- III.A.27. The professional suffix (e.g., M.D., Ph.D.) for the new party, if applicable.
- **III.A.28.** The professional position title of the new party.
- **III.A.29.** The organization name representing the new party.
- III.A.30. The organization FDA-assigned Facility Establishment Identifier (FEI) number, if applicable.
  Note: To obtain or retrieve an FEI number, applicants can use the FEI Search Portal at <a href="https://www.accessdata.fda.gov/scripts/feiportal/index.cfm?action=portal.login">https://www.accessdata.fda.gov/scripts/feiportal/index.cfm?action=portal.login</a>, and/or contact FEI Search Portal support at <a href="mailto:feiportal@fda.hhs.gov">feiportal@fda.hhs.gov</a> for any FEI number-related questions.
- III.A.31. The organization D&B DUNS number, if applicable.
- **III.A.32.** The street address for the new party (including street number, street name and type, suffix direction, etc.). The street address cannot be a P.O. Box.
- **III.A.33.** Additional street address information for the new party (including apartment, suite, or building number) that you were not able to include in III.A.32.
- III.A.34. The city of the new party.
- **III.A.35.** The state, province, or territory of the new party.
- III.A.36. The country of the new party.
- **III.A.37.** The ZIP or postal code of the new party.
- III.A.38. The phone number of the new party (include country code, if applicable, and area code).
- III.A.39. The fax number of the new party, if applicable (include country code, if applicable, and area code).
- III.A.40. The email address of the new party.

## Part B: Request for Change in Ownership

Complete Part B if you selected "Request for Change in Ownership" in Section III.1. Use the Continuation Page button within the form to list additional applications, submissions, and/or product names to be transferred, as needed.

A change in or transfer of ownership is for applicants (companies) that manufacture or sell tobacco products and transfers the rights and responsibilities for their applications and submissions to another company. The **former applicant** is the party that is listed in FDA's records to date. The **new applicant** is the party taking responsibility for the submissions. The new and former applicant must sign and submit certain information and statements to complete the transfer. This information is submitted as a general correspondence for all applications/submissions and not as an amendment to each application. The former applicant and new applicant must submit all information as outlined in Section III, Part B as applicable to their role in the transfer.

*Note*: The former applicant may select checkboxes for former and new if they are submitting all requirements on behalf of both parties. The new applicant **cannot** submit on behalf of the former. FDA will only process the request for change in ownership upon receipt of the request from the **former applicant**.

For change in ownership requests that include Premarket Tobacco Product Applications (PMTA) or Substantial Equivalence (SE) Reports, FDA Form 4057a and/or FDA Form 3965a are required. A single form can be provided for transfer requests that include multiple submission types. Changes in ownership that do not include SE or PMTA submissions do not require FDA Form 4057a or FDA Form 3965a, though we encourage the use of forms.

The following are submission types that FDA will transfer:

- Marketing Applications
  - o 910 Premarket Tobacco Application (PMTA)
  - o 905(j)(1) Substantial Equivalence Reports (SE)
  - o 905(j)(3) Exemption from Substantial Equivalence (EX)
  - o 911 Modified Risk Tobacco Product Application (MRTPA)
- Submissions
  - o 910(g) Investigational Tobacco Use (IU)
  - o General Correspondence and Meeting Requests (TC)
  - o Master Files (MF)
  - o Grandfather Determination Requests (GF)
  - o Pre-Existing Tobacco Products (PX)
  - o Warning Plans (WP)
  - o Other Media Notifications (OM)
- **III.B.1.** Indicate the applications, submissions, and product names to be transferred, including the STN, PD numbers, and product names.
- **III.B.2.** Indicate the effective date of the transfer.
- III.B.3. Select the checkbox(es) to indicate the items included in the transfer request.

## Part C: Meeting Request

Complete Part C if you selected "Meeting Request" in Section III.1. This is a request for a formal meeting which may include topics such as study design, earlier versions of the product, etc. Use the Continuation Page button within the form to list additional products, as needed.

- **III.C.1.** The topic of the meeting.
- **III.C.2.** The purpose of the meeting.
- **III.C.3.** The format of the meeting.
- **III.C.4.** Indicate whether the meeting information package is included. If not, select "No" and provide the expected date of the submission.
- **III.C.5.** List the name of the product(s) to be discussed at the meeting.
- **III.C.6.** The use of the product.
- **III.C.7.** The product category (if applicable).
- **III.C.8.** The STN.PD# of the product (if applicable).
- III.C.9. Select the checkbox(es) to indicate the items included in the meeting request.